


Phase 1 of the AMPLIFY-201 trial: Vaccine ELI-002 2P shows promise for treating cancers with residual tumor markers

25 cancer patients

Positive for both KRAS mutation* and residual tumor marker following standard surgery and chemotherapy




ELI-002 vaccination



Fixed dose of **Amph-Peptides-2P**
+ progressively increasing dose
of **Amph-CpG-7909**

- 0.1 mg : 3 patients
- 0.5 mg: 6 patients
- 2.5 mg: 5 patients
- 5.0 mg: 5 patients
- 10.0 mg: 6 patients

Vaccine accumulates in lymph nodes,
improving immune response by T cells



*KRAS mutations are often linked to cancer, affecting regulation of cell division and differentiation

ELI-002 is safe and effective

No observed dose-limiting toxicity



Recommended dose of
Amph-CpG-7909 for phase 2:

10 mg

T cell response against
KRAS mutation

84%
(21 patients)

Tumor biomarker
reduction

84%
(21 patients)

Complete tumor
biomarker clearance

24%
(6 patients)

Relapse-free survival



Patients with T cell response **below** threshold: **4.01 months**
Patients with T cell response **above** threshold: **Not reached**

These findings pave the way for **phase 2 of the AMPLIFY-7P**
trial broadening to target G12D, R, V, C, A, S and G13D KRAS
mutations and can aid the development of **new treatments**
for both infectious diseases and cancer